
MOGRIFY-derived transcription factors preserve functional vision
Mogrify will present preclinical proof-of-concept data at FLORetina-ICOOR 2026 in support its first-in-class therapy designed to protect and regenerate the retina in patients with retinal disorders. The company’s lead programme uses transcription factor-mediated direct reprogramming to convert müller glial cells into functional photoreceptors within the retina. … Read More
